TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2218229120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Ramesh Singh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Castration-resistant prostate cancer (CRPC) poses a major clinical challenge with the androgen receptor (AR) remaining to be a critical oncogenic player. Several lines of evidence indicate that AR induces a distinct transcriptional program after androgen deprivation in CRPCs. However, the mechanism triggering AR binding to a distinct set of genomic loci in CRPC and how it promotes CRPC development remain unclear. We demonstrate here that atypical ubiquitination of AR mediated by an E3 ubiquitin ligase TRAF4 plays an important role in this process. TRAF4 is highly expressed in CRPCs and promotes CRPC development. It mediates K27-linked ubiquitination at the C-terminal tail of AR and increases its association with the pioneer factor FOXA1. Consequently, AR binds to a distinct set of genomic loci enriched with FOXA1- and HOXB13-binding motifs to drive different transcriptional programs including an olfactory transduction pathway. Through the surprising upregulation of olfactory receptor gene transcription, TRAF4 increases intracellular cAMP levels and boosts E2F transcription factor activity to promote cell proliferation under androgen deprivation conditions. Altogether, these findings reveal a posttranslational mechanism driving AR-regulated transcriptional reprogramming to provide survival advantages for prostate cancer cells under castration conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
- Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204.
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030.
ORCID-Profile: Ramesh Singh, Huan Meng, Lance Edward V Lumahan, Steven Nguyen, Subhamoy Dasgupta, Li Qin, Bokai Zhu, Feng Yang, Bert W O'Malley, Ping Yi
Förderung
- NCI NIH HHS
- NICHD NIH HHS
- NIEHS NIH HHS
- U.S. Department of Defense
- HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
- HHS | NIH | National Institute of Environmental Health Sciences
Zitieren
APA
Singh, R., Meng, H., Shen, T., Lumahan, L. E. V., Nguyen, S., Shen, H., Dasgupta, S., Qin, L., Karri, D., Zhu, B., Yang, F., Coarfa, C., O'Malley, B. W., & Yi, P. (2023). TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2218229120
Vancouver
Singh R, Meng H, Shen T, Lumahan LEV, Nguyen S, Shen H, et al. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2218229120
BibTeX
@article{Singh2023,
author = {Singh, Ramesh and Meng, Huan and Shen, Tao and Lumahan, Lance Edward V and Nguyen, Steven and Shen, Hong and Dasgupta, Subhamoy and Qin, Li and Karri, Dileep and Zhu, Bokai and Yang, Feng and Coarfa, Cristian and O'Malley, Bert W and Yi, Ping},
title = {TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2218229120}
}
EUVIMED